Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

Rhea-AI Summary

Skye Bioscience (Nasdaq: SKYE), a clinical-stage biotech company specializing in obesity and metabolic health disorders, has scheduled its Q2 2025 earnings call for August 7, 2025, at 1:30 p.m. PT/4:30 p.m. ET.

The company will release its financial results and business update after market close on the same day. Investors can access the live webcast, earnings release, financial tables, and presentation materials through Skye's Investor Relations website. A replay will be available following the call.

SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, August 7, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss its second quarter 2025 financial results. The Company will issue its financial results and business update press release after the market closes on the same day.

The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Please join the call 5-10 minutes prior to the scheduled start time. Following the call, a replay will be available at the same website.

About Skye Bioscience

Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.

CONTACTS

Investor Relations
ir@skyebioscience.com
(858) 410-0266

LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306

Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889

FAQ

When will Skye Bioscience (SKYE) report Q2 2025 earnings?

Skye Bioscience will report Q2 2025 earnings after market close on August 7, 2025, followed by a conference call at 1:30 p.m. PT/4:30 p.m. ET.

How can investors access Skye Bioscience's (SKYE) Q2 2025 earnings call?

Investors can access the live webcast through Skye's Investor Relations website, where earnings release, financial tables, and investor presentation will also be available.

What time is Skye Bioscience's (SKYE) Q2 2025 earnings call?

The earnings call is scheduled for 1:30 p.m. PT/4:30 p.m. ET on August 7, 2025. Participants are advised to join 5-10 minutes before the start time.

What is Skye Bioscience's (SKYE) main business focus?

Skye Bioscience is a clinical-stage biotechnology company focused on developing new therapeutic pathways for obesity and other metabolic health disorders.